Pharmaceutical News

RSS

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Emerson Ecologics to exclusively distribute Sedona Labs Pro probiotic products

Emerson Ecologics, LLC, the leading provider of professional-grade nutritional supplements to the healthcare practitioner market, announces a new strategic partnership with Nutri-Health as the exclusive distributor for their practitioner brand, Sedona Labs Pro™. Effective immediately, all customer service, marketing and order fulfillment for the complete line of Sedona Labs Pro products will be handled by Emerson Ecologics.

3 Aug 2010

Oxygen Biotherapeutics collaborates with U.S. Navy to develop treatment for DCS

Oxygen Biotherapeutics, Inc. today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to conduct preclinical trials to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte perfluorocarbon emulsion (PFCE) for the prevention and treatment of decompression sickness and related injuries.

3 Aug 2010

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

A single intravenous dose of the anesthetic agent ketamine appears to reduce symptoms of depression within 40 minutes among those with bipolar disorder who have not responded to other treatments, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

The vast majority of pediatricians and family physicians nationally are offering the human papillomavirus (also called HPV) vaccine, though fewer physicians are strongly encouraging it for 11- to 12-year-old girls as recommended by national guidelines, according to a survey in the September issue of Pediatrics, the journal of the American Academy of Pediatrics.

3 Aug 2010

Alphavirus vector induce immune responses in people with advanced cancer: Researchers

There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.

3 Aug 2010

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

3 Aug 2010

Patrys secures funding of up to A$15 million to support advancement of clinical products

Patrys Limited (ASX: PAB), a company focused on the development of natural human antibodies for the treatment of cancer, announced today that it has secured up to A$15 million in funding.

3 Aug 2010

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.

2 Aug 2010

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that preclinical data on three of its pipeline candidates will be highlighted at the XXIII International Complement Workshop taking place August 1-5, 2010, in New York City.

2 Aug 2010

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Ben-Gurion University of the Negev Professor Varda Shoshan-Barmatz has been awarded a three-year, $600,000 grant from the U.S. Leukemia & Lymphoma Society to develop target-specific, anti-cancer drugs.

2 Aug 2010

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

RegeneRx Biopharmaceuticals, Inc. today announced that a research team from the Molecular Medicine Unit at UCL-Institute of Child Health in London reported preclinical findings that Thymosin beta 4, is essential to healthy heart development and embryonic survival.

2 Aug 2010

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 63 percent of surveyed U.S. gastroenterologists prescribe Abbott's Humira off-label for the treatment of ulcerative colitis. According to the new report entitled Treatment Algorithms in Ulcerative Colitis, surveyed gastroenterologists most often prescribe Humira for ulcerative colitis for patients with loss of response, intolerance or no response to Centocor Ortho Biotech's Remicade.

2 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

Inergetics receives initial purchase order from New Marketlink for Resurgex Select

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a $112,500 purchase order for Resurgex Select from New Marketlink Pharmaceutical Corporation "New Marketlink."

2 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Almac's solutions to support biopharma companies by adopting biomarker strategies

Almac today announced the launch of Biomarkers for biopharma a range of solutions specifically designed to meet the needs of the biopharma industry.Almac's solutions are to support biopharma companies in adopting biomarker strategies to enable them to better understand their drug, improve their drug's success rate, improve the drug's value and ultimately maximise their drug's potential.

2 Aug 2010

Painkiller combinations cost more but are less effective: Report

In a new article in the journal Australian Prescriber, there is a warning that combination painkillers cause more side effects and may not provide the relief promised. This comes from the National Prescribing Service (NPS), Australia's medicine review body.

1 Aug 2010

Stop & Shop Supermarket announces voluntary recall of Nature's Promise Alfalfa, Zesty Sprouts

The Stop & Shop Supermarket Company has announced a voluntary recall of Nature's Promise Alfalfa and Zesty Sprouts because they have the potential to be contaminated with listeria monocytogenes.

31 Jul 2010

Pharmaceutical News

Curis reports net loss of $2.1 million for second-quarter 2010

Emerson Ecologics to exclusively distribute Sedona Labs Pro probiotic products

Oxygen Biotherapeutics collaborates with U.S. Navy to develop treatment for DCS

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

Survey on administrating human papillomavirus vaccine for cervical cancer prevention

Alphavirus vector induce immune responses in people with advanced cancer: Researchers

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

Patrys secures funding of up to A$15 million to support advancement of clinical products

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Thymosin beta 4 is essential to healthy heart development, embryonic survival: Research

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Inergetics receives initial purchase order from New Marketlink for Resurgex Select

Xeomin receives FDA approval for treatment of cervical dystonia

Almac's solutions to support biopharma companies by adopting biomarker strategies

Painkiller combinations cost more but are less effective: Report

Stop & Shop Supermarket announces voluntary recall of Nature's Promise Alfalfa, Zesty Sprouts

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News